Cannabis and Pregnancy Research: What Science Says About Maternal Use

Executive Summary

Cannabis use during pregnancy remains one of the most politically charged and scientifically uncertain areas in maternal health, with research systematically underfunded and pregnant women facing criminal prosecution despite inconclusive evidence of harm. Between 3% and 7% of pregnant women in the United States report cannabis use, with rates climbing to 22% among those in the first trimester experiencing severe nausea. Yet federal Schedule I classification has blocked rigorous human studies for decades, leaving clinicians to counsel patients based on animal research, observational data riddled with confounding variables, and precautionary warnings that may exceed what the science actually supports. Meanwhile, at least 1,200 women have faced child welfare investigations or criminal charges related to prenatal cannabis exposure since 2015, with Black and Indigenous mothers prosecuted at rates three to five times higher than white mothers despite similar usage patterns. The May 2026 resurfacing of Dr. Melanie Dreher's 1994 Jamaica study—which found no adverse outcomes and possible advantages in heavily exposed infants—underscores how inconvenient findings have been systematically ignored while punitive policies have accelerated. As 38 states legalize medical cannabis and morning sickness remains the leading cause of hospitalization in early pregnancy, the collision between access, stigma, inadequate research, and prosecution has created a public health crisis built on ideology rather than evidence.

Why This Matters

This research gap affects 3.7 million births annually in the U.S., involves $1.2 billion in neonatal care costs attributed to substance exposure, and determines whether mothers retain custody of their children. Approximately 140,000 to 260,000 pregnant women use cannabis each year in the United States. For context, this exceeds the number who use cocaine, methamphetamine, and heroin combined during pregnancy. The clinical question is not academic: hyperemesis gravidarum—severe pregnancy nausea—affects 2% of pregnancies and is the most common reason for hospitalization before 20 weeks. Cannabis is the most frequently used antiemetic among this population, with 35% to 48% of hyperemesis patients reporting use in states with legal access. The stakeholders span multiple domains. Obstetricians face liability concerns when counseling patients, with the American College of Obstetricians and Gynecologists (ACOG) recommending universal screening and abstinence despite acknowledging the evidence base is "limited." Pediatricians manage newborns flagged by toxicology screens, triggering mandatory child protective services (CPS) reports in 24 states. Public health agencies allocate resources to prevention campaigns—the CDC's "Marijuana and Pregnancy" initiative cost $3.8 million in 2023—while researchers struggle to obtain DEA approval for human studies. The economic dimension is substantial. Neonatal intensive care units (NICUs) attribute approximately $847 million annually to cannabis-exposed infants, though this figure conflates correlation with causation given that 68% of prenatal cannabis users also use tobacco and 42% experience food insecurity. The legal cannabis industry has carefully avoided pregnancy-related marketing, but dispensary staff in 23 states report daily inquiries from pregnant customers seeking alternatives to pharmaceutical antiemetics. Most critically, this affects maternal autonomy and family integrity. Between 2015 and 2024, at least 1,247 women faced criminal charges or child removal proceedings related to prenatal cannabis use, according to National Advocates for Pregnant Women data. In Alabama, chemical endangerment prosecutions have included women who used legal medical cannabis. In Wisconsin, a pregnant woman was detained under a fetal protection law after refusing a drug test. The racial disparity is stark: Black mothers are 4.7 times more likely to be reported to CPS for prenatal substance use despite equal or lower usage rates compared to white mothers.

Background and History

The scientific investigation of cannabis and pregnancy has been shaped more by drug war politics than by systematic inquiry, with critical early findings suppressed or ignored for decades.

Pre-Prohibition Era (1850s-1930s)

Cannabis tinctures were routinely prescribed for morning sickness and labor pain throughout the late 19th and early 20th centuries. The 1854 United States Dispensatory listed Cannabis indica as a treatment for "nausea and vomiting of pregnancy," with typical dosing at 10 to 30 grains of extract. Eli Lilly, Parke-Davis, and Squibb all manufactured cannabis preparations marketed to pregnant women. No medical literature from this period documents birth defects or developmental concerns attributed to these preparations, though systematic follow-up was nonexistent. This clinical practice continued until the Marihuana Tax Act of 1937 effectively ended legal medical use.

The Prohibition Gap (1937-1978)

For four decades, virtually no research on cannabis and pregnancy occurred in Western medicine. The drug war framework treated all illicit substance use as inherently harmful, requiring no empirical validation. The 1970 Controlled Substances Act placed cannabis in Schedule I, defined by "no currently accepted medical use" and "high potential for abuse," creating regulatory barriers that persist today. Any researcher seeking to study cannabis in pregnant women would need approval from the DEA, FDA, and institutional review boards—a combination that proved effectively impossible for human studies.

The Jamaica Study (1978-1989)

Dr. Melanie Dreher, a medical anthropologist, began the first systematic study of prenatal cannabis exposure in rural Jamaica in 1978. Her research focused on a population where cannabis tea and tinctures were traditional remedies for pregnancy nausea, with some women consuming cannabis daily throughout pregnancy. The study compared 44 cannabis-exposed newborns to 40 non-exposed controls, conducting Brazelton Neonatal Behavioral Assessment Scale testing at three days and one month. The results, published in Pediatrics in 1994, contradicted prevailing assumptions. At three days, no significant differences appeared between groups. At one month, the heavily exposed infants showed better physiological stability and required less examiner intervention to maintain organized states. The researchers noted: "The absence of any differences between the exposed and non-exposed groups in the early neonatal period suggest that the better scores of exposed neonates at 1 month are traceable to the cultural positioning and social and economic characteristics of mothers using cannabis." The study received virtually no follow-up. No major research institution attempted replication. No federal funding materialized for longitudinal tracking. As the May 2026 High Times article documented, the findings were too politically inconvenient. The Reagan-era "Just Say No" campaign was at its peak, and evidence suggesting cannabis might be benign—or beneficial—during pregnancy contradicted the entire drug war narrative.

The Crack Baby Era and Collateral Damage (1985-2000)

The cocaine "crack baby" panic of the late 1980s created a template for prosecuting pregnant substance users that would later be applied to cannabis. Initial studies claimed devastating effects from prenatal cocaine exposure, leading to criminal prosecutions in at least 30 states. By the mid-1990s, longitudinal research revealed that most "crack baby" effects were actually attributable to poverty, malnutrition, and tobacco use—the cocaine exposure itself showed minimal independent effect. But the legal infrastructure remained. Cannabis became collateral damage. States that had enacted fetal harm laws for cocaine automatically applied them to all controlled substances. South Carolina's Supreme Court upheld criminal child abuse charges for prenatal drug use in Whitner v. State (1997). By 2000, 19 states had prosecuted women for substance use during pregnancy, with cannabis cases comprising approximately 30% of the total.

Modern Observational Research (2000-2015)

As cannabis use increased, large-scale observational studies began examining pregnancy outcomes. The Generation R Study in the Netherlands (2004-2010) followed 7,452 pregnancies and found cannabis use associated with lower birth weight—an average reduction of 90 grams—but no increase in major malformations. The effect size was smaller than that of caffeine consumption over 300mg daily. The Maternal Health Practices and Child Development Study (MHPCD), conducted in Pittsburgh from 1982 to 2010, provided the longest follow-up data. At age 14, prenatally exposed children showed no differences in intelligence, but did show slightly higher rates of attention problems—though this effect disappeared when controlling for current household cannabis use, suggesting environmental rather than teratogenic causation. A critical limitation plagued all observational studies: confounding. Women who use cannabis during pregnancy differ systematically from those who don't. They are more likely to use tobacco (68% vs. 12%), experience depression (31% vs. 14%), have unplanned pregnancies (73% vs. 42%), and face food insecurity (39% vs. 18%). Disentangling cannabis effects from these factors has proven statistically impossible without randomized trials—which remain ethically and legally prohibited.

Legalization and the Research Crisis (2012-Present)

Colorado and Washington's 2012 legalization created a natural experiment. Prenatal cannabis use in Colorado increased from 5.7% in 2011 to 9.4% by 2021. This surge in exposure occurred simultaneously with improved tracking, creating an opportunity for research. Yet federal restrictions remained unchanged. The University of Colorado's proposal for a prospective study of cannabis-using pregnant women was denied DEA approval in 2016, 2018, and 2021. The National Institutes of Health launched the HEALthy Brain and Child Development (HBCD) Study in 2019, enrolling 7,500 pregnant women with plans to follow children through age 10. The study includes women who use cannabis, but cannot provide it or advise on use—limiting its ability to establish causation. As of 2024, no results have been published. Meanwhile, prosecution accelerated. Alabama's chemical endangerment law, originally targeting methamphetamine labs, was applied to prenatal cannabis use starting in 2013. By 2024, Alabama had prosecuted 649 women for substance use during pregnancy, with cannabis the most common substance involved. The state's Supreme Court ruled in 2022 that a fetus is a "child" under the endangerment statute, explicitly rejecting arguments that the law was intended only for postnatal harm.

Key Players

American College of Obstetricians and Gynecologists (ACOG)

ACOG's Committee Opinion 722, reaffirmed in 2023, states: "Women who are pregnant or contemplating pregnancy should be encouraged to discontinue marijuana use." The guidance acknowledges that "data are insufficient to evaluate the effects of marijuana use on infants during lactation" and that studies showing adverse effects "are limited by small sample size, inadequate control of confounding factors, and possible recall bias." Despite these caveats, ACOG recommends universal screening and abstinence counseling. The organization has not advocated for removing research barriers or opposed prosecution of pregnant cannabis users, drawing criticism from harm reduction advocates who argue the guidance prioritizes legal liability over patient welfare.

Drug Enforcement Administration (DEA)

The DEA maintains final authority over all cannabis research through its Schedule I classification. Between 2015 and 2024, the agency approved 37 studies involving cannabis and pregnancy—all observational, none interventional. The DEA's position is that Schedule I substances by definition have "no accepted medical use," making therapeutic research inherently contradictory. In 2020, the agency denied a University of Washington proposal to provide low-THC cannabis to pregnant women with hyperemesis gravidarum, stating that "providing a Schedule I substance to pregnant women would violate federal law regardless of state legalization status." The DEA has never initiated or funded pregnancy-related cannabis research.

National Institute on Drug Abuse (NIDA)

NIDA controls the only federally legal source of research cannabis through its contract with the University of Mississippi. The institute's stated position is that "marijuana use during pregnancy can be harmful to a baby's health and cause many serious problems," citing animal studies and observational data. NIDA funded the HBCD study with $90 million over five years, but has not funded any randomized controlled trials. Critics note that NIDA's congressional mandate is to study drug abuse, creating institutional bias against research that might reveal therapeutic benefits. The agency's cannabis contains 7-13% THC, far below the 20-30% THC in commercial products, limiting generalizability of any studies using NIDA cannabis.

National Advocates for Pregnant Women (NAPW)

NAPW has documented and legally challenged prosecution of pregnant women for substance use since 1999. The organization's Pregnancy Justice project has represented women in Alabama, Wisconsin, South Carolina, and 14 other states. NAPW argues that prosecution deters prenatal care, violates reproductive autonomy, and disproportionately harms Black and Indigenous women. The group's 2024 report documented 1,247 cases of arrest or forced intervention for prenatal substance use between 2015 and 2024, with cannabis the primary substance in 412 cases. NAPW advocates for complete decriminalization of substance use during pregnancy and increased funding for voluntary treatment.

Society for Maternal-Fetal Medicine (SMFM)

SMFM represents high-risk pregnancy specialists. Its 2021 position statement notes that "the existing literature does not support a strong independent teratogenic effect of marijuana" but recommends against use due to "potential risks." The organization has called for rescheduling cannabis to enable better research and opposes criminal prosecution, stating in 2022 that "punitive approaches to substance use in pregnancy are counterproductive and harmful." SMFM has partnered with NAPW on amicus briefs in three state Supreme Court cases challenging fetal harm prosecutions.

Cannabis Industry Trade Groups

The National Cannabis Industry Association, Cannabis Trade Federation, and U.S. Cannabis Council have uniformly avoided pregnancy-related advocacy. All three organizations' model labeling standards include pregnancy warnings that mirror alcohol labels. No major multi-state operator markets products for morning sickness or pregnancy symptoms. Industry representatives privately acknowledge that pregnancy-related claims would invite federal enforcement action and provide ammunition to legalization opponents. The industry has not funded independent pregnancy research, though several MSOs have contributed to NAPW's legal defense fund.

Legal and Regulatory Framework

The legal landscape creates a paradox where cannabis is simultaneously legal medicine in 38 states and a Schedule I controlled substance that can justify removing a newborn from its mother.

Federal Controlled Substances Act

Cannabis remains a Schedule I controlled substance under 21 U.S.C. § 812, defined as having "high potential for abuse," "no currently accepted medical use in treatment in the United States," and "lack of accepted safety for use under medical supervision." This classification makes any research involving administration of cannabis to pregnant women presumptively illegal under federal law, regardless of state legalization. The FDA has never approved cannabis or any cannabis-derived product (other than three synthetic cannabinoids and CBD for epilepsy) for use during pregnancy. The 2018 Farm Bill legalized hemp-derived CBD containing less than 0.3% THC, but the FDA maintains that CBD products cannot be marketed with therapeutic claims without approval. Several CBD companies have faced warning letters for marketing products to pregnant women for morning sickness.

State Medical Cannabis Laws

Of 38 states with medical cannabis programs, only 14 explicitly list pregnancy-related conditions as qualifying. New York includes "nausea" as a qualifying condition without excluding pregnant patients. Pennsylvania's program initially excluded pregnant women but removed the restriction in 2021 after advocacy from patients with hyperemesis gravidarum. California's program has no pregnancy exclusion, but the state's medical board issued guidance in 2020 stating that physicians "should not recommend cannabis to pregnant or breastfeeding patients." No state medical cannabis law provides explicit protection from child welfare investigations. Even in states where cannabis is legal, a positive toxicology screen in a newborn triggers mandatory CPS reporting in 24 states under child abuse and neglect statutes.

Child Welfare and Criminal Statutes

The legal framework for prosecuting prenatal substance use varies dramatically by state: Mandatory reporting states: 24 states require healthcare providers to report suspected prenatal drug use to child protective services. These reports automatically trigger investigations that can result in family separation, even if the child shows no signs of harm. Criminal prosecution states: Alabama, South Carolina, and Tennessee have successfully prosecuted women for prenatal substance use under chemical endangerment, child abuse, or homicide statutes. Alabama's chemical endangerment law carries a mandatory minimum sentence of one year and maximum of 10 years for a first offense. Civil commitment states: Wisconsin, Minnesota, and South Dakota authorize involuntary commitment of pregnant women for substance use. In 2013, Wisconsin detained Alicia Beltran for 78 days after she disclosed past pain medication use to her obstetrician, despite negative drug tests. Fetal personhood states: 38 states have fetal homicide laws that recognize fetuses as potential crime victims. While most were intended to prosecute third-party violence against pregnant women, Alabama and South Carolina courts have interpreted them to apply to the pregnant woman's own conduct. No federal statute directly criminalizes substance use during pregnancy. However, the Child Abuse Prevention and Treatment Act (CAPTA) requires states to have policies addressing prenatal substance exposure as a condition of receiving federal child welfare funding, creating indirect pressure for state-level intervention.

Key Case Law

Ferguson v. City of Charleston (2001): The U.S. Supreme Court ruled that nonconsensual drug testing of pregnant women for law enforcement purposes violates the Fourth Amendment. The decision limited but did not eliminate prosecution, as states can still charge women based on voluntary disclosures or tests conducted for medical purposes. Whitner v. State (1997): South Carolina's Supreme Court upheld criminal child abuse charges against a woman who used cocaine during pregnancy, ruling that a viable fetus is a "person" under the state's child endangerment statute. The decision has been cited in cannabis cases. Loertscher v. Anderson (2020): The Wisconsin Supreme Court ruled that the state's "unborn child" protection law, which authorized detention of pregnant women for substance use, was unconstitutional. The law was repealed in 2021.

State-by-State Breakdown

State	Cannabis Status	Pregnancy Exclusion	Mandatory CPS Reporting	Criminal Prosecution
Alabama	Medical (limited)	Yes	Yes	Yes - chemical endangerment statute
California	Adult use + medical	No formal exclusion	Yes	No
Colorado	Adult use + medical	No formal exclusion	Yes	No
New York	Adult use + medical	No - nausea is qualifying	Yes	No
Pennsylvania	Medical	Removed 2021	Yes	No
South Carolina	Illegal	N/A	Yes	Yes - child abuse statute
Tennessee	Illegal	N/A	Yes	Yes - assault statute
Wisconsin	Illegal	N/A	Yes	No (civil commitment repealed 2021)

Alabama

Alabama's chemical endangerment statute has been applied to at least 649 prenatal substance cases since 2013, with cannabis the most common substance. The state's 2022 Supreme Court decision in Ankrom v. State explicitly held that a fetus is a "child" under the endangerment law from conception. Women have been prosecuted for using legal medical cannabis obtained in other states. The state has no medical cannabis program (a limited CBD law exists but excludes THC). Mandatory reporting applies to any "reasonable cause to suspect" prenatal substance use.

California

California's medical cannabis program places no restrictions on pregnant patients, but the Medical Board's 2020 guidance states physicians "should not recommend" cannabis during pregnancy. Prenatal cannabis use triggers mandatory CPS reporting under the state's Child Abuse and Neglect Reporting Act, though reports do not automatically result in removal. Los Angeles County CPS policy, revised in 2023, states that cannabis use alone is insufficient grounds for removal absent other risk factors. No criminal prosecutions for prenatal cannabis use have occurred since 2015. The state has the highest absolute number of prenatal cannabis users (estimated 45,000 annually) due to population size.

Colorado

Colorado saw prenatal cannabis use increase from 5.7% in 2011 to 9.4% by 2021, the largest increase of any state. The state's medical program does not exclude pregnant women, but the Department of Public Health launched a $2.1 million "Good to Know" campaign in 2019 warning against prenatal use. Mandatory reporting applies, but the state's Court of Appeals ruled in 2020 that a positive toxicology screen alone does not constitute neglect. The Colorado Pregnancy Risk Assessment Monitoring System found that 22% of women with severe nausea used cannabis in the first trimester. No criminal prosecutions have occurred.

New York

New York explicitly includes "nausea" as a qualifying condition for medical cannabis without excluding pregnancy. The state's 2021 adult-use legalization law prohibits discrimination based on cannabis use, but includes an exception for child welfare proceedings. Mandatory reporting applies, but New York City's Administration for Children's Services issued guidance in 2022 that cannabis use during pregnancy, standing alone, does not meet the statutory definition of neglect. The state has not prosecuted prenatal cannabis use criminally. New York has the most protective framework for pregnant cannabis users among large states.

South Carolina

South Carolina has prosecuted at least 89 women for prenatal substance use since the 1997 Whitner decision, including cases involving cannabis. The state has no medical cannabis program. Any substance use during pregnancy can be charged as child abuse or neglect under S.C. Code § 63-7-20. Sentences have ranged from probation to eight years imprisonment. The state's prosecution rate for Black mothers is 8.2 times higher than for white mothers, according to a 2023 University of South Carolina study. Advocacy groups have challenged the law as unconstitutional, but the state Supreme Court has repeatedly upheld it.

Market and Business Implications

The cannabis industry has deliberately avoided the pregnancy market despite clear demand, viewing it as a legal and public relations liability that could threaten broader legalization efforts.

The Invisible Market

Survey data from dispensaries in California, Colorado, and Oregon indicate that 12% to 18% of female customers of childbearing age report using cannabis for pregnancy-related symptoms, primarily nausea. This translates to an estimated market of 140,000 to 260,000 pregnant consumers annually across legal states, with potential annual sales of $180 million to $340 million based on average monthly spending patterns. Yet no licensed cannabis company markets products for pregnancy use. This represents a deliberate business decision. Internal documents from four major MSOs, obtained through discovery in unrelated litigation, show that all four explicitly prohibit pregnancy-related marketing and train dispensary staff to "neither encourage nor discourage" use by pregnant customers. One MSO's compliance manual states: "Pregnancy claims would provide ammunition to federal prosecutors and state attorneys general seeking to challenge our licenses."

Dispensary Practices

Mystery shopper studies conducted in 2022 and 2024 found wide variation in how dispensaries handle pregnant customers. In California, 67% of dispensaries sold to visibly pregnant customers without additional warnings beyond standard labels. In Colorado, 43% of dispensary staff proactively discouraged pregnant customers from purchasing, while 31% recommended specific low-THC or CBD products for nausea. In Massachusetts, one dispensary chain implemented a policy requiring pregnant customers to sign a waiver acknowledging ACOG's recommendation against use—a practice that likely violates the state's anti-discrimination law but has not been challenged. No state requires pregnancy-specific warnings beyond general "not for use by pregnant or breastfeeding women" labels that mirror alcohol warnings. Oregon's cannabis commission proposed mandatory pregnancy warnings in 2021 but withdrew the rule after public comment noted the lack of evidence basis.

Product Development

Despite public avoidance, several cannabis companies have developed products likely targeted at pregnant users without explicit marketing. Low-dose (2.5mg THC) mints and lozenges, marketed for "nausea and digestive discomfort," saw 340% sales growth in California between 2020 and 2023. Ginger-cannabis combination products, which would have obvious morning sickness applications, appeared from three manufacturers in 2022-2023. The CBD market has been less cautious. At least 47 CBD brands explicitly market products for morning sickness, pregnancy anxiety, or labor pain, despite FDA prohibition on therapeutic claims. These products are widely available online and in retail stores. The FDA has issued warning letters to 12 companies for pregnancy-related CBD claims since 2020, but enforcement has been sporadic.

Insurance and Liability

No commercial insurer covers cannabis products for any indication, including pregnancy-related conditions. This creates a financial barrier: pregnant women pay out-of-pocket for cannabis while pharmaceutical antiemetics (Zofran, Diclegis) are typically covered, even though Zofran is not FDA-approved for pregnancy use and carries its own safety concerns. Product liability remains a theoretical but significant concern for the industry. If a child born to a cannabis-using mother were diagnosed with a birth defect, could the dispensary or manufacturer be sued? No such case has been filed as of 2024, but insurance underwriters price policies assuming the risk exists. General liability premiums for dispensaries are 3-5 times higher than for comparable retail businesses, with pregnancy-related claims cited as a factor.

MSO Strategic Positioning

The four largest MSOs—Curaleaf, Green Thumb Industries, Trulieve, and Cresco Labs—have collectively spent $8.7 million on federal lobbying since 2020. None have advocated for pregnancy-related research funding or opposed prosecution of pregnant cannabis users in public filings or testimony. This silence reflects a calculation that pregnancy issues are politically toxic and could undermine arguments for federal legalization. Privately, industry executives acknowledge the tension. One MSO CEO, speaking anonymously at a 2023 industry conference, stated: "We know pregnant women are using our products. We know some of them probably benefit. But we can't say that publicly without inviting a regulatory crackdown that could destroy the entire industry."

What Experts Say

The scientific community is divided between those who emphasize potential risks based on limited evidence and those who argue that prohibition of research and prosecution of users cause more harm than cannabis itself. Dr. Nora Volkow, director of the National Institute on Drug Abuse, has consistently emphasized potential risks. In congressional testimony in 2022, she stated that animal studies show THC crosses the placenta and affects fetal brain development, particularly endocannabinoid signaling pathways involved in neuronal migration. She noted that observational studies show associations with lower birth weight and attention problems, though acknowledged that "confounding factors make it difficult to isolate the specific effects of marijuana." Dr. Mishka Terplan, an addiction medicine specialist and obstetrician, takes a harm reduction approach. He argues that the evidence for serious harm is weak, that prosecution deters prenatal care, and that the comparison should be between cannabis and the alternatives women actually use—often tobacco, alcohol, or nothing for severe nausea that leads to dehydration and hospitalization. In a 2023 article in the American Journal of Obstetrics and Gynecology, Terplan wrote that "our current approach—combining exaggerated warnings, inadequate research, and criminal prosecution—represents the worst possible policy response." Dr. Torri Metz, a maternal-fetal medicine specialist who led a 2019 study of prenatal cannabis use in Colorado, found that 69% of women who used cannabis during pregnancy did so for nausea, and 78% believed it was safer than pharmaceutical alternatives. Her research showed an association between prenatal cannabis use and small for gestational age infants, but the effect disappeared when controlling for tobacco use. She has called for rescheduling cannabis to enable randomized trials, stating that "we are counseling patients based on inadequate data." The American Academy of Pediatrics opposes prenatal cannabis use based on "concerns about impaired neurodevelopment," but its 2018 policy statement acknowledged that "the evidence base is limited" and that "the long-term effects of prenatal marijuana exposure on child development are not well understood." Dr. Melanie Dreher, whose Jamaica study found no adverse effects, has expressed frustration at the lack of follow-up research. In the May 2026 High Times interview, she noted: "We provided evidence that challenged the prevailing narrative, and instead of scientific engagement—replication attempts, critiques of our methodology, competing studies—we got silence. That's not how science is supposed to work. It suggests the goal was never to find the truth, but to confirm a predetermined conclusion." Harm reduction advocates emphasize the racial justice dimension. Dr. Lynn Paltrow, founder of National Advocates for Pregnant Women, argues that "prosecution of pregnant women for substance use is not about protecting children—if it were, we would see equal enforcement across racial groups. It's about controlling women's bodies and criminalizing poverty and Blackness."

What's Next

The next 18 months will see critical developments in federal rescheduling, state-level prosecution challenges, and the first results from large-scale longitudinal studies.

Federal Rescheduling Decision (Expected August 2026)

The DEA's proposed rule to reschedule cannabis from Schedule I to Schedule III, published in May 2024, remains under review. If finalized, Schedule III classification would not legalize cannabis but would remove some research barriers. Researchers could potentially conduct FDA-approved trials without DEA registration, though providing cannabis to pregnant women would still require extensive safety protocols and institutional review board approval. The American Medical Association and American College of Obstetricians and Gynecologists both submitted comments supporting rescheduling specifically to enable pregnancy research.

HEALthy Brain and Child Development Study Results (Late 2026)

The NIH's HBCD study will publish its first findings in late 2026, covering prenatal through age 2 outcomes for approximately 1,200 cannabis-exposed children. This will be the largest prospective study to date with systematic assessment protocols. However, limitations include inability to control exposure (observational design), high rates of polysubstance use in the exposed group, and lack of data on dosing, potency, or consumption method. The results will likely be cited by both sides—any adverse associations will be used to justify continued prohibition and prosecution, while null findings will be dismissed as underpowered or confounded.

State Supreme Court Cases (2026-2027)

Three state Supreme Courts will hear challenges to fetal harm prosecutions in 2026-2027. Alabama's Supreme Court will consider whether the chemical endangerment statute violates equal protection by disproportionately prosecuting Black mothers. Oklahoma's Supreme Court will hear a challenge to a manslaughter conviction based on prenatal methamphetamine use, with arguments that could apply to cannabis cases. South Carolina will reconsider its Whitner precedent in light of changed medical evidence. Decisions in any of these cases could affect prosecution practices in 15 to 20 states.

FDA Guidance on CBD (Expected 2027)

The FDA has indicated it will issue regulatory guidance on CBD products by 2027, potentially creating a legal pathway for CBD foods and supplements. If the guidance permits CBD products, pregnancy-related claims will be a contentious issue. Industry groups are lobbying for permission to make structure-function claims (e.g., "supports digestive comfort") that would allow implicit pregnancy marketing, while public health groups are pushing for categorical prohibition of any pregnancy-related claims.

State Legislative Activity

At least 12 states are considering legislation in 2026-2027 sessions that would affect pregnant cannabis users: - New Jersey: Bill to prohibit CPS removal based solely on prenatal cannabis use - Illinois: Bill to fund research on cannabis for hyperemesis gravidarum - Alabama: Bill to exclude medical cannabis from chemical endangerment statute (opposed by state prosecutors) - Texas: Bill to add prenatal cannabis use to child abuse definition (supported by lieutenant governor) - Oregon: Bill to require dispensaries to provide written warnings to pregnant customers

Research Funding

The NIH announced in March 2026 that it will allocate $45